GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sharps Technology Inc (NAS:STSS) » Definitions » Debt-to-EBITDA

STSS (Sharps Technology) Debt-to-EBITDA : -0.26 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Sharps Technology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sharps Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $3.76 Mil. Sharps Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Sharps Technology's annualized EBITDA for the quarter that ended in Dec. 2024 was $-14.62 Mil. Sharps Technology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sharps Technology's Debt-to-EBITDA or its related term are showing as below:

STSS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.43   Med: -0.29   Max: -0.16
Current: -0.43

During the past 5 years, the highest Debt-to-EBITDA Ratio of Sharps Technology was -0.16. The lowest was -0.43. And the median was -0.29.

STSS's Debt-to-EBITDA is ranked worse than
100% of 440 companies
in the Medical Devices & Instruments industry
Industry Median: 1.42 vs STSS: -0.43

Sharps Technology Debt-to-EBITDA Historical Data

The historical data trend for Sharps Technology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sharps Technology Debt-to-EBITDA Chart

Sharps Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
- -0.16 - - -0.43

Sharps Technology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.32 -0.26

Competitive Comparison of Sharps Technology's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Sharps Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sharps Technology's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sharps Technology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sharps Technology's Debt-to-EBITDA falls into.


;
;

Sharps Technology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sharps Technology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.764 + 0) / -8.853
=-0.43

Sharps Technology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.764 + 0) / -14.62
=-0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Sharps Technology  (NAS:STSS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sharps Technology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sharps Technology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sharps Technology Business Description

Traded in Other Exchanges
N/A
Address
105 Maxess Road, Suite 124, Melville, NY, USA, 11747
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
Executives
Robert Michael Hayes director, officer: Chief Executive Officer 75 BROOKSHIRE DRIVE, YOUNGSVILLE NC 27596
Andrew R. Crescenzo officer: Chief Financial Officer C/O ENZO BIOCHEM, 527 MADISON AVENUE, NEW YORK NY 10022
Timothy James Ruemler director 3311 RIVERPARK CT., BENITA SPRINGS FL 34134
Alan R. Blackman director, officer: CIO and COO 11502 ROBLES DR. REPP PLACE, TEMPLE TERRACE FL 33617
Paul K Danner director
Soren Bo Christiansen director 4059 SPRING VALLEY ROAD, DOYLESTOWN PA 18902
Brenda Baird Simpson director 7336 PRAIRIE STAR COURT,, PARKER CO 80134
Jason L. Monroe director 14527 LINDALE ROSE LANE, HUMBLE TX 77379
Barry Boris Berler officer: CTO and Inventor 77 HERZL STREET, RAMAT GAN L3 5244352